NCT07116070 Sarcopenia and Related Factors in Patients With Multiple Sclerosis
| NCT ID | NCT07116070 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Selcuk University |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-01-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2025-06-01 with a primary completion date of 2026-01-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple Sclerosis (MS) is a chronic disease affecting the central nervous system, exhibiting autoimmune and neurodegenerative properties. Neurological deficits, mobility limitations, and decreased muscle strength are commonly observed in MS patients as the disease progresses. The literature indicates that low physical activity levels and neurological deficits in individuals with MS can lead to decreased muscle mass and functional losses. Sarcopenia is a condition characterized by decreased skeletal muscle mass and strength associated with aging and chronic diseases, and studies on the prevalence of sarcopenia in MS patients are limited. Recent studies have revealed a high prevalence of sarcopenia in MS patients, which can have negative effects on physical performance, quality of life, and disease progression. Low muscle mass in MS patients can accelerate the loss of motor function and increase the level of disability. Additionally, nutritional deficiencies and low protein intake seen in MS patients are among the factors that accelerate muscle loss. Studies examining the relationship between MS and sarcopenia in the literature emphasize the importance of early diagnosis and intervention to improve patients' quality of life and functional independence. Factors such as muscle strength, physical activity level, and nutritional status should be assessed to determine the risk of sarcopenia in MS patients. This study was designed to determine the prevalence of sarcopenia in patients with Multiple Sclerosis (MS) and to examine the relationship between sarcopenia and fatigue, disability level (EDSS), nutritional status, and physical activity level. In this context: * The prevalence of sarcopenia in MS patients will be determined, * The relationship between sarcopenia and muscle strength, physical performance, and body composition will be evaluated, * The effects of nutrition and physical activity on sarcopenia in MS patients will be investigated.
Eligibility Criteria
Inclusion Criteria: * Being 18 years of age or older, * Having been diagnosed with Multiple Sclerosis (confirmed by a neurologist), * Being in a stable phase of the disease (having not had an attack in the last 3 months), * Having preserved walking ability (EDSS score ≤6.5), * Being able to give informed consent to participate in the study. Exclusion Criteria: * Having another neuromuscular disease. * Having developed significant muscle loss within the last 6 months due to use of corticosteroids or immunosuppressive therapy. * Having systemic diseases that can cause muscle loss, such as cancer, rheumatic diseases, or severe metabolic disorders. * Having undergone major surgery or a history of serious trauma within the last 3 months. * Being pregnant or breastfeeding.
Contact & Investigator
İsmail ÖZSOY, Assoc. Prof. Dr.
PRINCIPAL INVESTIGATOR
Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye
Frequently Asked Questions
Who can join the NCT07116070 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07116070 currently recruiting?
Yes, NCT07116070 is actively recruiting participants. Contact the research team at mehmetkaan.altunok@selcuk.edu.tr for enrollment information.
Where is the NCT07116070 trial being conducted?
This trial is being conducted at Konya, Turkey (Türkiye).
Who is sponsoring the NCT07116070 clinical trial?
NCT07116070 is sponsored by Selcuk University. The principal investigator is İsmail ÖZSOY, Assoc. Prof. Dr. at Selcuk University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Konya, Türkiye. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.